Roche advances skin cancer trials as part of combination therapy strategy

ZURICH, Nov 7 (Reuters) - Roche is pressing ahead with two

skin cancer trials that combine its immunotherapy Tecentriq with

other drugs after early data showed the treatments were

well-tolerated and effective in a small number of patients, the

company said Monday.

Read more